Characteristics of the study subjects
| . | All subjects . | NAFL− . | NAFL+ . |
|---|---|---|---|
| n | 24 | 8 | 16 |
| Histological liver fat (%) | 38.5 ± 6.8 | 2.6 ± 1.2 | 56.4 ± 6.5* |
| Women/men | 14/10 | 4/4 | 10/6 |
| Age (years) | 44 ± 2 | 47 ± 4 | 42 ± 3 |
| Body weight (kg) | 105 ± 6 | 85 ± 9 | 116 ± 8† |
| BMI (kg/m2) | 37.1 ± 2.4 | 29.9 ± 3.8 | 40.8 ± 2.6† |
| Components of the MetS | |||
| Waist circumference (cm) | 113 ± 4 | 85 ± 9 | 116 ± 8 |
| Systolic blood pressure (mmHg) | 133 ± 2 | 130 ± 5 | 134 ± 3 |
| Diastolic blood pressure (mmHg) | 83 ± 2 | 78 ± 3 | 86 ± 2† |
| fS triglycerides (mmol/l) | 1.7 ± 0.2 | 1.1 ± 0.2 | 1.9 ± 0.2† |
| fS HDL cholesterol (mmol/l) | 1.5 ± 0.1 | 2 ± 0.3 | 1.3 ± 0.1† |
| fP glucose (mmol/l) | 5.9 ± 0.2 | 5.3 ± 0.2 | 6.1 ± 0.3 |
| Other parameters | |||
| fS insulin (mU/l) | 12 ± 2 | 6 ± 1 | 15 ± 3† |
| fS C-peptide (nmol/l) | 0.9 ± 0.1 | 0.6 ± 0.1 | 1.1 ± 0.1‡ |
| fS FFA (μmol/l) | 588 ± 45 | 509 ± 90 | 628 ± 49 |
| fS adiponectin (μg/ml) | 9.7 ± 1 | 12.3 ± 2.1 | 8.4 ± 1§ |
| fP PAI-1 (ng/ml) | 31 ± 3 | 24 ± 6 | 35 ± 3 |
| fS LDL cholesterol (mmol/l) | 2.7 ± 0.2 | 2.7 ± 0.3 | 2.7 ± 0.2 |
| fS ALT (units/l) | 87 ± 13 | 97 ± 21 | 82 ± 17 |
| fS AST (units/l) | 53 ± 6 | 55 ± 9 | 53 ± 8 |
| MCV (fl) | 90 ± 1 | 90 ± 1 | 90 ± 1 |
| Daily alcohol dose | 0.5 ± 0.2 | 0.4 ± 0.2 | 0.5 ± 0.2 |
| . | All subjects . | NAFL− . | NAFL+ . |
|---|---|---|---|
| n | 24 | 8 | 16 |
| Histological liver fat (%) | 38.5 ± 6.8 | 2.6 ± 1.2 | 56.4 ± 6.5* |
| Women/men | 14/10 | 4/4 | 10/6 |
| Age (years) | 44 ± 2 | 47 ± 4 | 42 ± 3 |
| Body weight (kg) | 105 ± 6 | 85 ± 9 | 116 ± 8† |
| BMI (kg/m2) | 37.1 ± 2.4 | 29.9 ± 3.8 | 40.8 ± 2.6† |
| Components of the MetS | |||
| Waist circumference (cm) | 113 ± 4 | 85 ± 9 | 116 ± 8 |
| Systolic blood pressure (mmHg) | 133 ± 2 | 130 ± 5 | 134 ± 3 |
| Diastolic blood pressure (mmHg) | 83 ± 2 | 78 ± 3 | 86 ± 2† |
| fS triglycerides (mmol/l) | 1.7 ± 0.2 | 1.1 ± 0.2 | 1.9 ± 0.2† |
| fS HDL cholesterol (mmol/l) | 1.5 ± 0.1 | 2 ± 0.3 | 1.3 ± 0.1† |
| fP glucose (mmol/l) | 5.9 ± 0.2 | 5.3 ± 0.2 | 6.1 ± 0.3 |
| Other parameters | |||
| fS insulin (mU/l) | 12 ± 2 | 6 ± 1 | 15 ± 3† |
| fS C-peptide (nmol/l) | 0.9 ± 0.1 | 0.6 ± 0.1 | 1.1 ± 0.1‡ |
| fS FFA (μmol/l) | 588 ± 45 | 509 ± 90 | 628 ± 49 |
| fS adiponectin (μg/ml) | 9.7 ± 1 | 12.3 ± 2.1 | 8.4 ± 1§ |
| fP PAI-1 (ng/ml) | 31 ± 3 | 24 ± 6 | 35 ± 3 |
| fS LDL cholesterol (mmol/l) | 2.7 ± 0.2 | 2.7 ± 0.3 | 2.7 ± 0.2 |
| fS ALT (units/l) | 87 ± 13 | 97 ± 21 | 82 ± 17 |
| fS AST (units/l) | 53 ± 6 | 55 ± 9 | 53 ± 8 |
| MCV (fl) | 90 ± 1 | 90 ± 1 | 90 ± 1 |
| Daily alcohol dose | 0.5 ± 0.2 | 0.4 ± 0.2 | 0.5 ± 0.2 |
Data are means ± SE.
P < 0.001,
P < 0.05,
P < 0.01,
0.1 > P > 0.05, for subjects without (NAFL−) versus with (NAFL+) NAFLD. ALT, alanine aminotransferase; ASP, aspartate aminotransferase; fP, fasting plasma, fS, fasting serum; MCV, mean corpuscular volume; MetS, metabolic syndrome; NA, not applicable.